Renishaw Wins Funding for Antibiotic Resistance Assay

Share Article

Renishaw Diagnostics Ltd, a subsidiary of FTSE 250 listed Renishaw plc, has won funding from Innovate UK to accelerate development of a diagnostic assay that will identify patients carrying bacteria resistant to an important last line in antibiotic therapy.

Lab development at Renishaw Diagnostics

Renishaw Diagnostics Ltd, a subsidiary of FTSE 250 listed Renishaw plc, has won funding from Innovate UK to accelerate development of a diagnostic assay that will identify patients carrying bacteria resistant to an important last line in antibiotic therapy. The development contract, worth £150,000, has been awarded as part of a £10M, two-phase competition to promote the development of new diagnostic products and services for use in stratified medicine.

The project, to be carried out in collaboration with the Diagnostic Evidence Cooperative (DEC) and researchers at the Freeman Hospital in Newcastle, will develop a PCR based diagnostic test to identify patients carrying bacteria resistant to the carbapenem class of antibiotics, often considered the last resort in the treatment of many bacterial infections. The test will provide fast, reliable detection of the most prevalent gene families known to confer resistance and will allow testing of at-risk patients prior to hospital admission, supporting appropriate patient management and providing information for infection control.

Rupert Jones, General Manager of Renishaw Diagnostics Ltd said, “We are delighted that the strength of our funding application has been recognised by Innovate UK. Antibiotic resistance is a growing global issue and diagnostics will become an increasingly important part of patient management decisions, including more targeted use of antimicrobial therapies. We look forward to working with our collaborators to apply our unique detection technology in this important area.”

About SBRI ‘Stratified medicine: connecting the UK infrastructure’ competition

The competition aims to accelerate and/or increase the development and adoption of innovative diagnostic tools in order to offer better targeted treatment to patients within the UK healthcare system. It also aims to demonstrate the benefits of companies working within the UK ‘enabling infrastructure', which is made up of specialist organisations that can help companies understand healthcare needs and design, evaluate and deliver their products and services into the NHS.

About Renishaw Diagnostics Limited

Renishaw Diagnostics Limited is part of the Renishaw Group, a world leader in engineering, medical device and spectroscopy technologies. The company is focussed on the development and commercialisation of the RenDx multiplex assay system to provide automated, multiplex, high sensitivity in vitro diagnostics of infectious disease. The platforms first CE marked assay, for the detection of the most common causative agents of invasive fungal disease, was launched in 2015.

Renishaw Diagnostics Limited is based in Glasgow, Scotland and further information can be found at http://www.renishaw.com/diagnostics

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Malcolm Price
Renishaw plc
+44 1453 524131
Email >
Visit website